Brammer Bio, which was acquired by Thermo Fisher Scientific earlier this year, is seeking tax increment financing for a proposed new manufacturing facility in Norton, Massachusetts. More: Brammer Bio seeking tax increment financing for proposed new manufacturing site in Massachusetts
read moreFacing rising pressure to its generics business and plummeting sales, Amneal’s investors have been looking for a shakeup at the top. Ultimately, shareholders looked to the past to lead the drugmaker into the future. More: Paul Bisaro vaulted now-struggling Amneal
read moreSanofi has suffered countless negative headlines stemming from a Dengvaxia safety scandal in the Philippines. But in a twist, officials are now considering using the vaccine again. More: Philippine officials consider Sanofi's Dengvaxia—again—amid deadly outbreak Source: fierce
read moreBack in 2016, Roche’s Tecentriq became the first in its class of immuno-oncology drugs to break into the bladder cancer arena. And it’s now in position to become the first into the previously untreated market, too. More: Roche's Tecentriq goes
read moreHard on the heels of its next-gen migraine competitors, Eli Lilly’s Emgality has been looking for a turbo boost. Solid data in preventing migraines as a follow-up treatment could do the trick. More: Eli Lilly's Emgality staves off migraines when
read moreFor those who were vaccinated the risk of suffering a stroke was 16% lower than those who weren’t. More: Flu vaccine could reduce risk of death for elderly patients Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals